LTX 004
Alternative Names: LTX-004Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Leal Therapeutics
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action Protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Dementia
Most Recent Events
- 07 Jan 2025 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Leal Therapeutics pipeline, January 2025)
- 07 Jan 2025 Preclinical trials in Dementia in USA (unspecified route) (Leal Therapeutics pipeline, January 2025)